Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 37.50 GBp
Change Today 0.00 / 0.00%
Volume 12.5K
As of 6:43 AM 05/5/15 All times are local (Market data is delayed by at least 15 minutes).

futura medical plc (FUM) Snapshot

Open
37.50 GBp
Previous Close
37.50 GBp
Day High
37.50 GBp
Day Low
37.50 GBp
52 Week High
05/6/14 - 67.00 GBp
52 Week Low
01/21/15 - 26.25 GBp
Market Cap
37.1M
Average Volume 10 Days
50.0K
EPS TTM
-0.03 GBp
Shares Outstanding
99.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for FUTURA MEDICAL PLC (FUM)

Related News

No related news articles were found.

futura medical plc (FUM) Related Businessweek News

No Related Businessweek News Found

futura medical plc (FUM) Details

Futura Medical plc engages in the research and development of pharmaceutical drugs and medical devices in the United Kingdom. The company offers CSD500, a condom that incorporates an erectogenic compound to help men maintain a firmer erection during intercourse whilst wearing a condom; MED2002, a gel applied directly to the penis for the treatment of male erectile dysfunction; and PET500, a topical spray that enables men to prolong their sexual experience. Its pain relief management products, such as TPR100 and TIB200 incorporates a non-steroidal anti-inflammatory drug; and SPR300 a topical gel combines methyl salicylate and menthol. The company was incorporated in 2001 and is headquartered in Guildford, the United Kingdom.

7 Employees
Last Reported Date: 03/25/15
Founded in 2001

futura medical plc (FUM) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 199.8K GBP
Finance Director, Secretary, Financial Contro...
Total Annual Compensation: 129.7K GBP
Chief Scientific Officer and Adviser to the B...
Total Annual Compensation: --
Compensation as of Fiscal Year 2013.

futura medical plc (FUM) Key Developments

Futura Medical plc Reports Preliminary Group Earnings Results for the Year Ended December 31, 2014

Futura Medical plc reported preliminary earnings results for the year ended December 31, 2014. For the year, the Group reported revenue of £43,929 compared to £370,902, operating loss of £3.5 million compared to £2.5 million, loss before tax of £3.5 million compared to £2.5 million, total comprehensive loss attributable to owners of the parent company of £3.0 million or 3.35 pence per basic and diluted share compared to £2.2 million or 2.85 pence per basic and diluted share, net cash used in operating activities of £3.1 million compared to £2.0 million and purchase of plant and equipment of £7,793 compared to £5,048 for the last year.

Futura Medical plc Commences Pain Relief Portfolio Study

Futura Medical plc announced that the screening of subjects is under way in an important clinical study of its portfolio of three topical pain relief products, all of which benefit from the rapid skin permeation offered by the Company's transdermal delivery system, DermaSys®. The well characterised active ingredients in the three products comprise diclofenac, ibuprofen and methyl salicylate, codenamed TPR100, TIB200 and SPR300 respectively. The three products are being tested in a controlled induced pain model in which the skin of healthy volunteers will be carefully exposed to a controlled amount of ultra-violet light to increase the sensitivity of the skin to pain stimuli. This approach removes some of the subjectivity and variability associated with studying pain in patients being treated for painful conditions. The study is of a randomised, double blind, crossover design in a total of 60 subjects, divided into three groups of 20 who will receive one of TPR100, TIB200 or SPR300 and controls. Two different strengths of TPR100, Futura's novel diclofenac gel, will be compared against a market-leading diclofenac gel, against orally delivered diclofenac and against a placebo of TPR100's gel. TIB200, Futura's novel ibuprofen gel, will be compared against a market-leading ibuprofen-containing gel, against orally delivered ibuprofen and against a placebo of TIB200's gel. The endpoints for TPR100 and TIB200 include equivalence with the marketed topical products against which they are being compared and also how they compare with oral versions of the marketed products. Systemic absorption of the active ingredients will be studied to identify any differences in the absorption profiles of the test products and these will be correlated with the side effect profiles. In addition to equivalence, the study will identify any potential superiority of TPR100 and TIB200 compared with the marketed products, for example, onset of action, duration and/or degree of pain relief. SPR300 will be compared only against a placebo of the gel used in SPR300 as, following consultation with UK regulators, there is no appropriate marketed methyl salicylate product that can be used as an active comparator. The endpoints of the trial for all three products are designed to meet regulatory requirements as well as to help identify any potentially strong marketing claims. The results from the study are expected by the end of July.

Futura Medical plc to Report Fiscal Year 2014 Results on Mar 25, 2015

Futura Medical plc announced that they will report fiscal year 2014 results on Mar 25, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FUM:LN 37.50 GBp 0.00

FUM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for FUM.
View Industry Companies
 

Industry Analysis

FUM

Industry Average

Valuation FUM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 822.7x
Price/Book 3.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 819.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FUTURA MEDICAL PLC, please visit www.futuramedical.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.